Abbott has announced the world’s first implant of a dual-chamber pacemaker
Abbott Laboratories (Abbott) announced in February of 2022 that it had begun patient trials of a dual-chamber leadless pacemaker. Leadless pacemakers are minimally invasive and generally result in fewer complications than traditional pacemakers. Current leadless pacemakers can only be placed in one chamber of the heart while nearly 80% of people who receive pacemakers require a dual-chamber option. The development of a leadless pacemaker which could operate synchronously in two chambers of the heart would be significant for the industry.
Balance Sheet|New ActivityIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.